HALE DAVID F

Insider Reports History

Reporting-owner location: Encinitas, CA
Latest reporting-owner signature: /s/ Gerald T. Proehl, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for HALE DAVID F

Form 4 holding Director

Oncternal Therapeutics, Inc.

Security class: Common Stock
Shares / value: 29,673
Estimated value: $268,244
Report date: 23 Feb 2024
Price: $9.04
Ownership: By Hale BioPharma Ventures, LLC

Form 4 holding Director

BIOCEPT INC

Security class: Common Stock
Shares / value: 3,114
Estimated value: $12,663
Report date: 09 Dec 2021
Price: $4.07
Ownership: By LLC

Form 4 holding Director

Oncternal Therapeutics, Inc.

Security class: Common Stock
Shares / value: 917
Estimated value: $8,290
Report date: 23 Feb 2024
Price: $9.04
Ownership: By Hale Trading Company

Form 4 holding Director

Oncternal Therapeutics, Inc.

Security class: Common Stock
Shares / value: 714
Estimated value: $6,455
Report date: 23 Feb 2024
Price: $9.04
Ownership: Direct

Form 4 holding Director

BIOCEPT INC

Security class: Common Stock
Shares / value: 796
Estimated value: $3,237
Report date: 09 Dec 2021
Price: $4.07
Ownership: Direct

Form 4 holding Director

BIOCEPT INC

Security class: Common Stock
Shares / value: 101
Estimated value: $411
Report date: 09 Dec 2021
Price: $4.07
Ownership: By trust

Form 4 holding Director

Dermata Therapeutics, Inc.

Security class: Common Stock
Shares / value: 80,957
Estimated value
Report date: 23 Jan 2025
Price
Ownership: By Hale BioPharma Ventures LLC

Form 4 holding Director

Dermata Therapeutics, Inc.

Security class: Warrant (Right to Buy)
Shares / value: 78,741
Estimated value
Report date: 21 Jan 2025
Price
Ownership: By Hale BioPharma Ventures LLC
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

Oncternal Therapeutics, Inc.

Security class: Stock Options
Shares / value: 3,300
Estimated value
Report date: 20 Jun 2024
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

Dermata Therapeutics, Inc.

Security class: Stock Option (Right to Buy)
Shares / value: 2,500
Estimated value
Report date: 02 Jan 2026
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

Dermata Therapeutics, Inc.

Security class: Common Stock
Shares / value: 314
Estimated value
Report date: 21 Jan 2025
Price
Ownership: Direct

Form 4 holding Director

Dermata Therapeutics, Inc.

Security class: Common Stock
Shares / value: 148
Estimated value
Report date: 21 Jan 2025
Price
Ownership: By Hale Family Trust

Form 4 holding Director

Dermata Therapeutics, Inc.

Security class: Common Stock
Shares / value: 50
Estimated value
Report date: 21 Jan 2025
Price
Ownership: By Hale Trading Company L.P.

Insider Reports Filed by HALE DAVID F

4 DRMA

Dermata Therapeutics, Inc.

Report period: 02 Jan 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 06 Jan 2026, 20:00
Role: Director
Next action: Open filing details

4 DRMA

Dermata Therapeutics, Inc.

Report period: 21 Jan 2025
Transactions: 2
Transaction value: $0
Accepted by SEC: 23 Jan 2025, 17:00
Role: Director
Next action: Open filing details

4 DRMA

Dermata Therapeutics, Inc.

Report period: 13 Jan 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 14 Jan 2025, 18:56
Role: Director
Next action: Open filing details

4

Oncternal Therapeutics, Inc.

Report period: 20 Jun 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 24 Jun 2024, 16:05
Role: Director
Next action: Open filing details

4

Oncternal Therapeutics, Inc.

Report period: 23 Feb 2024
Transactions: 2
Transaction value: +$8,859
Accepted by SEC: 27 Feb 2024, 17:03
Role: Director
Next action: Open filing details

4 DRMA

Dermata Therapeutics, Inc.

Report period: 04 Jan 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 05 Jan 2024, 21:00
Role: Director
Next action: Open filing details

4

Oncternal Therapeutics, Inc.

Report period: 28 Jun 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 30 Jun 2023, 16:00
Role: Director
Next action: Open filing details

4 DRMA

Dermata Therapeutics, Inc.

Report period: 06 Oct 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 07 Oct 2022, 17:06
Role: Director
Next action: Open filing details

4 DRMA

Dermata Therapeutics, Inc.

Report period: 07 Jul 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 08 Jul 2022, 16:10
Role: Director
Next action: Open filing details

4

Oncternal Therapeutics, Inc.

Report period: 16 Jun 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 17 Jun 2022, 18:01
Role: Director
Next action: Open filing details

4 DRMA

Dermata Therapeutics, Inc.

Report period: 07 Apr 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 08 Apr 2022, 19:12
Role: Director
Next action: Open filing details

4 DRMA

Dermata Therapeutics, Inc.

Report period: 03 Jan 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 05 Jan 2022, 18:08
Role: Director
Next action: Open filing details

5

Oncternal Therapeutics, Inc.

Report period: 31 Dec 2021
Transactions: 1
Transaction value: $0
Accepted by SEC: 11 Feb 2022, 17:00
Role: Director
Next action: Open filing details

4

BIOCEPT INC

Report period: 09 Dec 2021
Transactions: 3
Transaction value: -$1,807
Accepted by SEC: 10 Dec 2021, 16:04
Role: Director
Next action: Open filing details

4 DRMA

Dermata Therapeutics, Inc.

Report period: 17 Aug 2021
Transactions: 14
Transaction value: $0
Accepted by SEC: 17 Aug 2021, 12:49
Role: Director, 10%+ Owner
Next action: Open filing details

3 DRMA

Dermata Therapeutics, Inc.

Report period: 12 Aug 2021
Transactions: 0
Transaction value: $0
Accepted by SEC: 12 Aug 2021, 19:35
Role: Director
Next action: Open filing details

4

BIOCEPT INC

Report period: 16 Jul 2021
Transactions: 1
Transaction value: $0
Accepted by SEC: 20 Jul 2021, 16:45
Role: Director
Next action: Open filing details

4

Oncternal Therapeutics, Inc.

Report period: 30 Jun 2021
Transactions: 1
Transaction value: -$17,428
Accepted by SEC: 02 Jul 2021, 17:01
Role: Director
Next action: Open filing details

4

Oncternal Therapeutics, Inc.

Report period: 25 May 2021
Transactions: 1
Transaction value: $0
Accepted by SEC: 27 May 2021, 18:06
Role: Director
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .